IntegraGen, Laboratoire Cerba Ink Cancer Biomarker Deal

Mar 08, 2017

|

NEW YORK (GenomeWeb) — IntegraGen announced today that it has signed an agreement giving Laboratoire Cerba the right to develop a tumor expression test based on its microRNA biomarker miR-31-3p.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

IntegraGen, Laboratoire Cerba Ink Cancer Biomarker Deal

To read the full story....

Breaking News

GenScript Biotech, IES Diagnostics Partner to Distribute SARS-CoV-2 Antibody Kit

NantHealth Lands $137.5M in Financing to Extend Debt Maturity Date

RenalytixAI, Joslin Diabetes Center Ink Kidney Disease IP Agreement

Calciscon Raises $2.7M in Series A Round

PerkinElmer Preliminary Q1 Revenues Grow 98 Percent; FDA Issues EUA for PCR COVID-19 Test

Cofactor Genomics Begins Multi-Site Clinical Trial for Immunotherapy Prediction Assay

A New Generation of PCR: At-home Testing and Preparing for Emerging Strains of COVID-19

What's Popular?

FDA-Led Group Evaluates Performance of RUO Liquid Biopsy Assays to Inform Practice Guidelines

Cofactor Genomics Begins Multi-Site Clinical Trial for Immunotherapy Prediction Assay

NantHealth Lands $137.5M in Financing to Extend Debt Maturity Date

Armed With $55M in New Funding, Nucleix to Further Invest in Early-Stage Lung Cancer Dx

Oncocyte AACR Data Expands Potential Applications for Immunotherapy Response Predictor

Sponsorships